Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 447

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.

Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy

Open access
Wei, Jun, Long, Lingyun, Zheng, Wenting, Dhungana, Yogesh, Lim, Seon Ah, Guy, Cliff, Wang, Yanyan, Wang, Yong-Dong, Qian, Chenxi, Xu, Beisi, KC, Anil, Saravia, Jordy, Huang, Hongling, Yu, Jiyang, Doench, John G., Geiger, Terrence L., Chi, Hongbo·2019·Nature

Abstract

Adoptive cell therapy represents a new paradigm in cancer immunotherapy, but it can be limited by the poor persistence and function of transferred T cells1. Here we use an in vivo pooled CRISPR–Cas9 mutagenesis screening approach to demonstrate that, by targeting REGNASE-1, CD8+ T cells are reprogrammed to long-lived effector cells with extensive accumulation, better persistence and robust effector function in tumours. REGNASE-1-deficient CD8+ T cells show markedly improved therapeutic efficacy against mouse models of melanoma and leukaemia. By using a secondary genome-scale CRISPR–Cas9 screening, we identify BATF as the key target of REGNASE-1 and as a rheostat that shapes antitumour responses. Loss of BATF suppresses the increased accumulation and mitochondrial fitness of REGNASE-1-deficient CD8+ T cells. By contrast, the targeting of additional signalling factors—including PTPN2 and SOCS1—improves the therapeutic efficacy of REGNASE-1-deficient CD8+ T cells. Our findings suggest that T cell persistence and effector function can be coordinated in tumour immunity and point to avenues for improving the efficacy of adoptive cell therapy for cancer. CRISPR–Cas9 mutagenesis screenings reveal that targeting REGNASE-1 leads to improved therapeutic efficacy of CD8+ T cells against mouse models of cancer, and identify BATF as a key target of REGNASE-1.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-019-1821-z

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 62 references

Cited by

See all 447

Metadata

Authors
Wei, J., Long, L., Zheng, W., Dhungana, Y., Lim, S. A., Guy, C., Wang, Y., Wang, Y.-D., Qian, C., Xu, B., KC, A., Saravia, J., Huang, H., Yu, J., Doench, J. G., Geiger, T. L., & Chi, H.
Venue
Nature
Published
2019-12-11
Volume
576
Issue
7787
Pages
471-476
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W2996644149
Cited by
447
References
62
FWCI
15.69
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy. https://app.cochat.ai/papers/10.1038/s41586-019-1821-z
The paper
Wei, J., Long, L., Zheng, W., Dhungana, Y., Lim, S. A., Guy, C., Wang, Y., Wang, Y.-D., Qian, C., Xu, B., KC, A., Saravia, J., Huang, H., Yu, J., Doench, J. G., Geiger, T. L., & Chi, H. (2019). Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy. Nature. https://doi.org/10.1038/s41586-019-1821-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.